- Home
- ICU vs CURX Comparison
ICU vs CURX Comparison
Compare ICU & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | CURX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ICU | CURX |
|---|---|---|
| Price | $4.94 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 115.7K | 65.9K |
| Earning Date | 05-14-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.23 |
| 52 Week High | $5.38 | $9.18 |
Technical Indicators
Market Signals| Indicator | ICU | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 71.29 | 28.59 |
| Support Level | $2.32 | N/A |
| Resistance Level | N/A | $0.40 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | 0.25 | -0.00 |
| Stochastic Oscillator | 83.06 | 2.02 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.